Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions

被引:8
作者
Li, Jian-ri [1 ,3 ]
Yang, Chi-rei [2 ]
Cheng, Chen-li [1 ]
Ho, Hao-chung [1 ]
Chiu, Kun-yuan [1 ]
Su, Chung-Kuang [1 ]
Chen, Wen-Ming [1 ]
Wang, Shian-Shiang [1 ]
Chen, Chuan-Shu [1 ]
Yang, Cheng-Kuang [1 ]
Ou, Yen-chuan [1 ]
机构
[1] Taichung Vet Gen Hosp, Div Urol, Dept Surg, Taichung 407, Taiwan
[2] China Med Univ Hosp, Dept Urol, Taichung, Taiwan
[3] Chung Shan Med Univ, Inst Med & Mol Toxicol, Taichung, Taiwan
关键词
Hand-foot skin reactions; Heparin; Multikinase inhibitor; Renal cell carcinoma; RENAL-CELL CARCINOMA; PHASE-II; SORAFENIB; SUNITINIB; TRIAL;
D O I
10.1007/s00520-012-1693-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study is to evaluate the efficacy of a protocol including topical heparin therapy for hand-foot skin reactions (HFSR) during multikinase (MKI) treatment. We prospectively collected 26 patients who had HFSRs during treatment with the MKIs, sunitinib, sorafenib, or axitinib. The age distribution ranged from 46 to 87 years, with a mean of 66 years. The distribution of HFSR severity was 12 patients with grade 1, 12 with grade 2, and 2 with grade 3. A heparin-containing topical ointment treatment, combined with hand-foot shock absorbers and skin moisturizers, was used at the lesion sites. Changes in the grade of HFSR, MKI dosage, and interruptions of MKI therapy were recorded. The results showed that 66.7 % of grade 1 patients were cured of disease, 83.3 % of grade 2 patients had improved symptoms, and both grade 3 patients (100 %) had improved symptoms and were downgraded to grade 2. Four (15.4 %) patients required reduction of MKI dosage, but there were no treatment interruptions or dropouts. Our protocol is beneficial in promoting resolution of HFSRs induced by MKIs. Further validation in large control studies should be investigated.
引用
收藏
页码:907 / 911
页数:5
相关论文
共 23 条
  • [1] Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
    Bhojani, Naeem
    Jeldres, Claudio
    Patard, Jean-Jacques
    Perrotte, Paul
    Suardi, Nazareno
    Hutterer, Georg
    Patenaude, Francois
    Oudard, Stephane
    Karakiewicz, Pierre I.
    [J]. EUROPEAN UROLOGY, 2008, 53 (05) : 917 - 930
  • [2] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Chen, Zhendong
    Tsao, Chao-Jung
    Qin, Shukui
    Kim, Jun Suk
    Luo, Rongcheng
    Feng, Jifeng
    Ye, Shenglong
    Yang, Tsai-Sheng
    Xu, Jianming
    Sun, Yan
    Liang, Houjie
    Liu, Jiwei
    Wang, Jiejun
    Tak, Won Young
    Pan, Hongming
    Burock, Karin
    Zou, Jessie
    Voliotis, Dimitris
    Guan, Zhongzhen
    [J]. LANCET ONCOLOGY, 2009, 10 (01) : 25 - 34
  • [3] Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non-Renal Cell Carcinoma: A Meta-analysis
    Chu, David
    Lacouture, Mario E.
    Weiner, Elizabeth
    Wu, Shenhong
    [J]. CLINICAL GENITOURINARY CANCER, 2009, 7 (01) : 11 - 19
  • [4] Toxicities of Targeted Therapy and Their Management in Kidney Cancer
    Di Lorenzo, Giuseppe
    Porta, Camillo
    Bellmunt, Joaquim
    Sternberg, Cora
    Kirkali, Ziya
    Staehler, Michael
    Joniau, Steven
    Montorsi, Francesco
    Buonerba, Carlo
    [J]. EUROPEAN UROLOGY, 2011, 59 (04) : 526 - 540
  • [5] Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era
    Di Lorenzo, Giuseppe
    Autorino, Riccardo
    Sternberg, Cora N.
    [J]. EUROPEAN UROLOGY, 2009, 56 (06) : 959 - 971
  • [6] Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, Bernard
    Eisen, Tim
    Stadler, Walter M.
    Szczylik, Cezary
    Oudard, Stephane
    Siebels, Michael
    Negrier, Sylvie
    Chevreau, Christine
    Solska, Ewa
    Desai, Apurva A.
    Rolland, Frederic
    Demkow, Tomasz
    Hutson, Thomas E.
    Gore, Martin
    Freeman, Scott
    Schwartz, Brian
    Shan, Minghua
    Simantov, Ronit
    Bukowski, Ronald M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) : 125 - 134
  • [7] Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
    Escudier, Bernard
    Szczylik, Cezary
    Hutson, Thomas E.
    Demkow, Tomasz
    Staehler, Michael
    Rolland, Frederic
    Negrier, Sylvie
    Laferriere, Nicole
    Scheuring, Urban J.
    Cella, David
    Shah, Sonalee
    Bukowski, Ronald M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1280 - 1289
  • [8] Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
    Hutson, Thomas E.
    Figlin, Robert A.
    Kuhn, John G.
    Motzer, Robert J.
    [J]. ONCOLOGIST, 2008, 13 (10) : 1084 - 1096
  • [9] Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
    Lee, W. J.
    Lee, J. L.
    Chang, S. E.
    Lee, M. W.
    Kang, Y. K.
    Choi, J. H.
    Moon, K. C.
    Koh, J. K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 (05) : 1045 - 1051
  • [10] Sorafenib in advanced hepatocellular carcinoma
    Llovet, Josep M.
    Ricci, Sergio
    Mazzaferro, Vincenzo
    Hilgard, Philip
    Gane, Edward
    Blanc, Jean-Frederic
    Cosme de Oliveira, Andre
    Santoro, Armando
    Raoul, Jean-Luc
    Forner, Alejandro
    Schwartz, Myron
    Porta, Camillo
    Zeuzem, Stefan
    Bolondi, Luigi
    Greten, Tim F.
    Galle, Peter R.
    Seitz, Jean-Francois
    Borbath, Ivan
    Haussinger, Dieter
    Giannaris, Tom
    Shan, Minghua
    Moscovici, Marius
    Voliotis, Dimitris
    Bruix, Jordi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) : 378 - 390